A review of the association between antipsychotic use and hyperprolactinaemia
A review of the association between antipsychotic use and hyperprolactinaemia
Recent evidence linking hyperprolactinaemia to longer-term clinical sequelae, including osteoporosis, hip fractures and possibly breast cancer, is increasing clinical awareness of the relevance of hyperprolactinaemia. A review of the literature finds clinical trials reporting some degree of comparative prolactin data among antipsychotics. Many of the randomised clinical trials (RCTs) do not report categorical rates of hyperprolactinaemia in contrast with the naturalistic studies, making it complex for clinicians to evaluate the extent and severity of hyperprolactinaemia.Hyperprolactinaemia is one of the commonest adverse events reported in clinical trials and can be found in association with all antipsychotics. The highest rates of hyperprolactinaemia are reported in association with risperidone and amisulpride, often as high as 80-90% of all female subjects and consistently greater than with the typical antipsychotics. Significant rates of hyperprolactinaemia of lesser severity and more transience have also been reported in association with other atypical antipsychotics.
hyperprolactinemia, male, *adverse effects, complications, clinical trials as topic, *drug therapy, research design, risk assessment, antipsychotic agents, mental disorders, risk factors, cross-sectional studies, female, evidence-based medicine, humans, *chemically induced
46-55
Bushe, Chris
cb7915e9-b24f-40f4-8d7c-02bb73274e93
Shaw, Michael
df193f67-691b-4221-9744-b8488c43e2e8
Peveler, Robert C.
93198224-78d9-4c1f-9c07-fdecfa69cf96
2008
Bushe, Chris
cb7915e9-b24f-40f4-8d7c-02bb73274e93
Shaw, Michael
df193f67-691b-4221-9744-b8488c43e2e8
Peveler, Robert C.
93198224-78d9-4c1f-9c07-fdecfa69cf96
Bushe, Chris, Shaw, Michael and Peveler, Robert C.
(2008)
A review of the association between antipsychotic use and hyperprolactinaemia.
Journal of Psychopharmacology, 22 (Supplement 2), .
(doi:10.1177/0269881107088435).
Abstract
Recent evidence linking hyperprolactinaemia to longer-term clinical sequelae, including osteoporosis, hip fractures and possibly breast cancer, is increasing clinical awareness of the relevance of hyperprolactinaemia. A review of the literature finds clinical trials reporting some degree of comparative prolactin data among antipsychotics. Many of the randomised clinical trials (RCTs) do not report categorical rates of hyperprolactinaemia in contrast with the naturalistic studies, making it complex for clinicians to evaluate the extent and severity of hyperprolactinaemia.Hyperprolactinaemia is one of the commonest adverse events reported in clinical trials and can be found in association with all antipsychotics. The highest rates of hyperprolactinaemia are reported in association with risperidone and amisulpride, often as high as 80-90% of all female subjects and consistently greater than with the typical antipsychotics. Significant rates of hyperprolactinaemia of lesser severity and more transience have also been reported in association with other atypical antipsychotics.
This record has no associated files available for download.
More information
Published date: 2008
Keywords:
hyperprolactinemia, male, *adverse effects, complications, clinical trials as topic, *drug therapy, research design, risk assessment, antipsychotic agents, mental disorders, risk factors, cross-sectional studies, female, evidence-based medicine, humans, *chemically induced
Identifiers
Local EPrints ID: 70102
URI: http://eprints.soton.ac.uk/id/eprint/70102
ISSN: 0269-8811
PURE UUID: 55a747cb-7eb1-42e4-8081-382d466b90a0
Catalogue record
Date deposited: 21 Jan 2010
Last modified: 14 Mar 2024 02:34
Export record
Altmetrics
Contributors
Author:
Chris Bushe
Author:
Michael Shaw
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
